Vas Narasimhan had held top jobs at Novartis before taking the reins last year. He’d handled big challenges, too, including an H1N1 vaccine shortage during a pandemic. But as he notes in an NYT interview, he wasn’t prepared for the
read moreBempegaldesleukin, Nektar’s lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist. More: FDA grants Opdivo combo Breakthrough Designation for melanoma Source: News
read moreIt is the only monthly anti-IL5 biologic approved in Europe that patients can take home. More: Nucala receives self-administration EU approval Source: News
read morePatients with Lynch syndrome have an increased risk of colorectal cancer. More: Aspirin should be offered to Lynch syndrome patients Source: News
read moreThe decision is based on evidence from the COMPASS study, which was stopped early after meeting its primary efficacy endpoint. More: NICE backs Bayer’s Xarelto Source: News
read moreThe mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not be a good thing, analysts say. More: Pfizer's GSK
read more© 1994 - 2026 B.M. Pharmaceuticals